Lucija Peterlin Mašič
Lucija Peterlin Mašič
Proffesor of medicinal chemistry and toxicology
Verified email at - Homepage
Cited by
Cited by
Rhodanine as a privileged scaffold in drug discovery
T Tomasic, LP Masic
Current Medicinal Chemistry 16 (13), 1596-1629, 2009
Bioactivation potential of thiophene-containing drugs
D Gramec, L Peterlin Mašič, M Sollner Dolenc
Chemical research in toxicology 27 (8), 1344-1358, 2014
Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation
T Tomašić, L Peterlin Mašič
Expert opinion on drug discovery 7 (7), 549-560, 2012
Arginine mimetics
L Peterlin-Mašič, D Kikelj
Tetrahedron 33 (57), 7073-7105, 2001
Bisphenol A and its analogs: Do their metabolites have endocrine activity?
DG Skledar, LP Mašič
Environmental toxicology and pharmacology 47, 182-199, 2016
Discovery of novel 5-benzylidenerhodanine and 5-benzylidenethiazolidine-2, 4-dione inhibitors of MurD ligase
N Zidar, T Tomašić, R Sink, V Rupnik, A Kovac, S Turk, D Patin, D Blanot, ...
Journal of medicinal chemistry 53 (18), 6584-6594, 2010
Mutagenicity and DNA damage of bisphenol A and its structural analogues in HepG2 cells
A Fic, M Sollner Dolenc, M Filipič, L Peterlin Mašić
Arhiv za higijenu rada i toksikologiju 64 (2), 189-199, 2013
Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site
T Tomasic, S Katsamakas, Z Hodnik, J Ilaš, M Brvar, T Solmajer, ...
Journal of medicinal chemistry 58 (14), 5501-5521, 2015
Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases
T Tomašić, L Peterlin Masic
Current Topics in Medicinal Chemistry 14 (1), 130-151, 2014
Discovery of benzothiazole scaffold-based DNA gyrase B inhibitors
M Gjorgjieva, T Tomašič, M Barančokova, S Katsamakas, J Ilaš, ...
Journal of medicinal chemistry 59 (19), 8941-8954, 2016
In silico discovery of 2-amino-4-(2, 4-dihydroxyphenyl) thiazoles as novel inhibitors of DNA gyrase B
M Brvar, A Perdih, M Oblak, LP Mašič, T Solmajer
Bioorganic & medicinal chemistry letters 20 (3), 958-962, 2010
5‐Benzylidenethiazolidin‐4‐ones as multitarget inhibitors of bacterial Mur ligases
T Tomašić, N Zidar, A Kovač, S Turk, M Simčič, D Blanot, ...
ChemMedChem: Chemistry Enabling Drug Discovery 5 (2), 286-295, 2010
Bioactivation of bisphenol A and its analogs (BPF, BPAF, BPZ and DMBPA) in human liver microsomes
J Schmidt, P Kotnik, J Trontelj, Ž Knez, LP Mašič
Toxicology in vitro 27 (4), 1267-1276, 2013
Synthesis and antibacterial activity of 5-ylidenethiazolidin-4-ones and 5-benzylidene-4, 6-pyrimidinediones
T Tomašić, N Zidar, M Mueller-Premru, D Kikelj, LP Mašič
European journal of medicinal chemistry 45 (4), 1667-1672, 2010
Arginine mimetic structures in biologically active antagonists and inhibitors
L Peterlin Masic
Current medicinal chemistry 13 (30), 3627-3648, 2006
Influence of metabolism on endocrine activities of bisphenol S
DG Skledar, J Schmidt, A Fic, I Klopčič, J Trontelj, MS Dolenc, M Finel, ...
Chemosphere 157, 152-159, 2016
ATP-binding site of bacterial enzymes as a target for antibacterial drug design
V Škedelj, T Tomašić, LP Mašič, A Zega
Journal of medicinal chemistry 54 (4), 915-929, 2011
Estrogenic and androgenic activities of TBBA and TBMEPH, metabolites of novel brominated flame retardants, and selected bisphenols, using the XenoScreen XL YES/YAS assay
A Fic, B Žegura, D Gramec, LP Mašič
Chemosphere 112, 362-369, 2014
Synthesis and biological evaluation of new glutamic acid-based inhibitors of MurD ligase
T Tomašić, N Zidar, V Rupnik, A Kovač, D Blanot, S Gobec, D Kikelj, ...
Bioorganic & medicinal chemistry letters 19 (1), 153-157, 2009
Physiologically based pharmacokinetic (PBPK) modeling of the bisphenols BPA, BPS, BPF, and BPAF with new experimental metabolic parameters: comparing the pharmacokinetic …
C Karrer, T Roiss, N von Goetz, D Gramec Skledar, L Peterlin Mašič, ...
Environmental health perspectives 126 (7), 077002, 2018
The system can't perform the operation now. Try again later.
Articles 1–20